Monoclonal antibodies against SDS-disrupted bovine papillomavirus type 1 (BPVl) were obtained from hybridomas prepared by fusing mouse myeloma cell line P3X63Ag8Ul with spleen cells from immunized BALB/c mice. Six hybridoma cell lines were obtained after testing supernatant fluids for positivity by the enzyme-linked immunosorbent assay using the immunogen as antigen and by indirect immunofluorescence (IF) on frozen sections of BPVl-induced bovine fibropapillomas. Monoclonal antibodies (AU1-AU6) from these hybridomas were then tested for reactivity by IF tests on BPV2-induced fibropapillomas and on human plantar warts and vulvar condylomas and by avidin-biotin complex tests on sections of formalin-fixed cervical dysplasias. One monoclonal antibody (AUl) was reactive with all tissues, four (AU3-AU6) were reactive with both BPVl and BPV2 fibropapillomas, and the remaining antibody (AU2) was only reactive with BPVl-induced fibropapillomas. All monoclonal antibodies reacted with the major capsid protein (mol. wt. 54,000) of BPVl, whereas five (AUl, AU3-AU6) reacted with the major capsid protein of BPV2. These results indicate that papillomavirus genus-specific, cross-reactive, and type-specific antigenic determinants are located on the major capsid protein of BPVl.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.